These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 19322705)

  • 21. The RAGE Axis: A Relevant Inflammatory Hub in Human Diseases.
    Rojas A; Lindner C; Schneider I; Gonzalez I; Uribarri J
    Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The RAGE signaling in osteoporosis.
    Zhou J; Liu S; Bi S; Kong W; Qian R; Xie X; Zeng M; Jiang X; Liao Z; Shuai M; Liu W; Cheng L; Wu M
    Biomed Pharmacother; 2023 Sep; 165():115044. PubMed ID: 37354815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.
    Lue LF; Yan SD; Stern DM; Walker DG
    Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):249-66. PubMed ID: 15975028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases.
    Byun K; Yoo Y; Son M; Lee J; Jeong GB; Park YM; Salekdeh GH; Lee B
    Pharmacol Ther; 2017 Sep; 177():44-55. PubMed ID: 28223234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAGE in inflammation: a new therapeutic target?
    Bierhaus A; Stern DM; Nawroth PP
    Curr Opin Investig Drugs; 2006 Nov; 7(11):985-91. PubMed ID: 17117586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.
    Yan SF; Ramasamy R; Schmidt AM
    Expert Rev Mol Med; 2009 Mar; 11():e9. PubMed ID: 19278572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AGE-RAGE stress: a changing landscape in pathology and treatment of Alzheimer's disease.
    Prasad K
    Mol Cell Biochem; 2019 Sep; 459(1-2):95-112. PubMed ID: 31079281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
    Schmidt AM; Yan SD; Wautier JL; Stern D
    Circ Res; 1999 Mar; 84(5):489-97. PubMed ID: 10082470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature.
    Yan SF; Ramasamy R; Schmidt AM
    Circ Res; 2010 Mar; 106(5):842-53. PubMed ID: 20299674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE).
    Xie J; Reverdatto S; Frolov A; Hoffmann R; Burz DS; Shekhtman A
    J Biol Chem; 2008 Oct; 283(40):27255-69. PubMed ID: 18667420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
    Ramasamy R; Yan SF; Schmidt AM
    Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    López-Díez R; Shen X; Daffu G; Khursheed M; Hu J; Song F; Rosario R; Xu Y; Li Q; Xi X; Zou YS; Li H; Schmidt AM; Yan SF
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1536-1547. PubMed ID: 28642238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAGE and cardiovascular disease.
    Park S; Yoon SJ; Tae HJ; Shim CY
    Front Biosci (Landmark Ed); 2011 Jan; 16(2):486-97. PubMed ID: 21196183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptors for Advanced Glycation End Products (RAGE): Promising Targets Aiming at the Treatment of Neurodegenerative Conditions.
    Koerich S; Parreira GM; de Almeida DL; Vieira RP; de Oliveira ACP
    Curr Neuropharmacol; 2023; 21(2):219-234. PubMed ID: 36154605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
    Rao NV; Argyle B; Xu X; Reynolds PR; Walenga JM; Prechel M; Prestwich GD; MacArthur RB; Walters BB; Hoidal JR; Kennedy TP
    Am J Physiol Cell Physiol; 2010 Jul; 299(1):C97-110. PubMed ID: 20375277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RAGE: a multi-ligand receptor unveiling novel insights in health and disease.
    Alexiou P; Chatzopoulou M; Pegklidou K; Demopoulos VJ
    Curr Med Chem; 2010; 17(21):2232-52. PubMed ID: 20459381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression.
    El-Far AH; Sroga G; Jaouni SKA; Mousa SA
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Periodontal disease and the oral-systemic connection: "is it all the RAGE?".
    Katz J; Wallet S; Cha S
    Quintessence Int; 2010 Mar; 41(3):229-37. PubMed ID: 20213024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress.
    Herold K; Moser B; Chen Y; Zeng S; Yan SF; Ramasamy R; Emond J; Clynes R; Schmidt AM
    J Leukoc Biol; 2007 Aug; 82(2):204-12. PubMed ID: 17513693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Potential of Receptor for Advanced Glycation End Products (RAGE) as a Therapeutic Target for Lung Associated Diseases.
    Khaket TP; Kang SC; Mukherjee TK
    Curr Drug Targets; 2019; 20(6):679-689. PubMed ID: 30457049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.